Skip to main content
. Author manuscript; available in PMC: 2021 Sep 13.
Published in final edited form as: Clin Cancer Res. 2019 Oct 10;26(5):984–989. doi: 10.1158/1078-0432.CCR-19-1457

Figure 1.

Figure 1.

Schematic representation of Probody therapeutic activation in the tumor microenvironment. Probody therapeutics are fully recombinant antibody prodrugs designed to remain relatively inactive systemically and to be activated specifically in the tumor microenvironment by tumor-associated proteases. Figure redrawn with permission from CytomX.